BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 21809181)

  • 1. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M; Frank M; Steichen O; Blanchard A
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS; Gradman AH; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren: the first direct renin inhibitor available for clinical use.
    Morganti A; Lonati C
    J Nephrol; 2011; 24(5):541-9. PubMed ID: 21786226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is there a need for direct renin inhibitors?].
    Grossman E
    Harefuah; 2008 Mar; 147(3):216-7, 278. PubMed ID: 18488862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.